Plus therapeutics announces initial patients successfully treated in respect-lm dose optimization trial for reyobiq™ in leptomeningeal metastases

Substantial clinical need expected to facilitate rapid overall trial enrollment substantial clinical need expected to facilitate rapid overall trial enrollment

PSTV Ratings Summary

PSTV Quant Ranking